AU2001259318A1 - A medicinal aerosol formulation - Google Patents

A medicinal aerosol formulation

Info

Publication number
AU2001259318A1
AU2001259318A1 AU2001259318A AU5931801A AU2001259318A1 AU 2001259318 A1 AU2001259318 A1 AU 2001259318A1 AU 2001259318 A AU2001259318 A AU 2001259318A AU 5931801 A AU5931801 A AU 5931801A AU 2001259318 A1 AU2001259318 A1 AU 2001259318A1
Authority
AU
Australia
Prior art keywords
aerosol formulation
medicinal aerosol
medicinal
formulation
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259318A
Inventor
Akwete L. Adjei
Anthony J. Cutie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeropharm Technology LLC
Original Assignee
Aeropharm Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology LLC filed Critical Aeropharm Technology LLC
Publication of AU2001259318A1 publication Critical patent/AU2001259318A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
AU2001259318A 2000-05-01 2001-05-01 A medicinal aerosol formulation Abandoned AU2001259318A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20124800P 2000-05-01 2000-05-01
US60201248 2000-05-01
US09702779 2000-10-31
US09/702,779 US6464959B1 (en) 2000-05-01 2000-10-31 Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
PCT/US2001/014043 WO2001082868A2 (en) 2000-05-01 2001-05-01 A medicinal aerosol formulation

Publications (1)

Publication Number Publication Date
AU2001259318A1 true AU2001259318A1 (en) 2001-11-12

Family

ID=26896552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259318A Abandoned AU2001259318A1 (en) 2000-05-01 2001-05-01 A medicinal aerosol formulation

Country Status (3)

Country Link
US (1) US6464959B1 (en)
AU (1) AU2001259318A1 (en)
WO (1) WO2001082868A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092154A1 (en) * 2001-04-26 2002-11-21 New England Pharmaceuticals, Inc. Metered dose delivery device for liquid and powder agents
JP2005513031A (en) * 2001-11-26 2005-05-12 アラクノーバ・セラピューティックス・リミテッド Use of a PPAR activator for the treatment of pulmonary fibrosis
US6992093B2 (en) 2002-05-02 2006-01-31 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Method of inhibiting lipofibroblast to myofibroblast transdifferentiation
US8293479B2 (en) 2002-05-02 2012-10-23 Los Angeles Biomedical Research Institute At Harbor Ucla Medical Center Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
EP1535065A4 (en) * 2002-06-11 2007-07-11 Burnham Inst Neuroprotective synergy of erythropoietin and insulin-like growth factor
US7591999B2 (en) * 2003-03-04 2009-09-22 Mitsubishi Tanabe Pharma Corporation Powdery preparation for nasal administration
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
WO2005004913A1 (en) * 2003-07-09 2005-01-20 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
EP0460064A4 (en) 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5635159A (en) 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
CN1088580C (en) 1994-12-22 2002-08-07 阿斯特拉公司 Aerosol drug formulations
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists

Also Published As

Publication number Publication date
WO2001082868A3 (en) 2002-04-11
US6464959B1 (en) 2002-10-15
WO2001082868A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2001224716A1 (en) A medicinal aerosol formulation
AU2001226233A1 (en) A medicinal aerosol formulation
EP1296723A4 (en) A medicinal aerosol formulation
AU2753001A (en) A medicinal aerosol formulation
AU4519001A (en) A medicinal aerosol formulation
AU2002218250A1 (en) Medicament dispenser
AU6310000A (en) Aerosol formulations
HUP0302311A3 (en) Medicinal aerosol formulations
AU2002223562A1 (en) Medicament dispenser
AUPR054400A0 (en) A castor
AU2001227535A1 (en) A core formulation
AU2001227532A1 (en) A core formulation
AU2001224718A1 (en) A medicinal aerosol formulation
AU2623401A (en) A medicinal aerosol formulation
AU2001259318A1 (en) A medicinal aerosol formulation
AUPR000900A0 (en) A berley dispenser
AU1141101A (en) Pharmaceutical aerosol formulations comprising s-salmeterol
HUP0600143A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii
AU2001227531A1 (en) A medicinal aerosol formulation
AU2001247123A1 (en) A medicinal aerosol formulation
EP1292283A4 (en) A medicinal aerosol formulation
AU2001267135A1 (en) Medicaments
AU2002215902A1 (en) Medicament dispenser
GB0014849D0 (en) Pharmaceutical aerosol formulation
AU2002223437A1 (en) Medicament dispenser